Navigation Links
Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
Date:8/1/2012

ROCHESTER, Minn.-- Researchers at Mayo Clinic have completed the world's first genome-wide sequencing analysis of peripheral T-cell lymphomas, unlocking the genetic secrets of this poorly understood and highly aggressive cancer of the immune system.

Andrew Feldman, M.D., a Mayo Clinic pathologist and Damon Runyon Clinical Investigator, and a team of researchers affiliated with Mayo's Center for Individualized Medicine and Mayo Clinic Cancer Center, found 13 genomic abnormalities that were seen in multiple peripheral T-cell lymphomas. Of particular interest, five of these abnormalities relate to production and behavior of the p53 protein -- often called the "guardian of the genome" because of the central role it plays in regulating cell life cycles and, therefore, suppressing cancers.

The study, entitled "Genome-wide Analysis Reveals Recurrent Structural Abnormalities of TP63 and other p53-related Genes in Peripheral T-cell Lymphomas," is scheduled for early release in the online edition of the journal Blood at 9 a.m. on Wednesday, Aug. 1, 2012.

"Every time I diagnose a peripheral T-cell lymphoma, I know that two out of three patients will succumb to that lymphoma," says Dr. Feldman. "That's a very unsatisfying feeling, and I hope that our research can help change those statistics."

Peripheral T-cell lymphomas account for about 12 percent of non-Hodgkin's lymphomas and carry remarkably high mortality rates. Fewer than 35 percent of patients live five years beyond diagnosis.

New diagnostic biomarkers (chemical or genetic clues in the body's system) and treatments aimed at specific subgroups of peripheral T-cell lymphomas could lead to improved outcomes, says Dr. Feldman. Developing these, however, has been a challenge for several reasons. Lymphomas that look remarkably similar under a microscope may differ substantially in their overall prognoses and responses to treatment. Additionally, scientists and doctors have a relatively poor understanding of how peripheral T-cell lymphomas develop and proliferate.

"The most common type of T-cell lymphoma is called 'not otherwise specified.' It's basically a wastebasket diagnosis because we don't understand enough about the specific genetic abnormalities to be able to pinpoint subtypes of T-cell lymphomas that might trigger different treatments by the treating oncologist," says Dr. Feldman.

Dr. Feldman's study will be used to improve diagnostic tests and develop targeted treatments for peripheral T-cell lymphoma.

Among the key findings in the genomic abnormalities of peripheral T-cell lymphoma are:

  • Thirteen recurrent chromosomal rearrangements
  • Five of the 13 rearrangements involve p53-related genes, important for tumor-suppressor function
  • Novel rearrangements involving the TP53 homologue and TP63, which were associated with shortened survival times
  • Four interchromosomal abnormalities, including the previously known ALK and DUSP22-IRF4 translocations

  • '/>"/>

    Contact: Sam Smith
    newsbureau@mayo.edu
    507-284-5005
    Mayo Clinic
    Source:Eurekalert

    Related medicine news :

    1. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
    2. First targeted nanomedicine to enter human clinical studies
    3. Clinical insight improves treatment with new lung cancer drug
    4. Clinical news alert from the American Academy of Orthopaedic Surgeons
    5. Mayo Clinic launches whole genome breast cancer study
    6. Mayo Clinic offers newly approved treatment for acid reflux disease
    7. NYU Langone experts present research, clinical advances at neurosurgeons meeting
    8. Mayo Clinic breast cancer study finds new type of mutation
    9. Kroenke honored for outstanding contributions in clinical research training
    10. Awards celebrate clinical research that can improve health and alleviate suffering
    11. Association for Psychological Science, SAGE launch Clinical Psychological Science
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2017)... ... February 27, 2017 , ... Hotze ... industry, announces Chris Brandl as its New Guest Director. , Brandl is ... corporations throughout his career. He began his professional career at Omnium Worldwide, now ...
    (Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been ... women who become dependent on opioid painkillers has fallen short. From 1999 until 2010, ... a 237% increase in fatal overdoses in male populations.(1) , The proportion of women ...
    (Date:2/27/2017)... ... February 27, 2017 , ... Orange County dentist, ... inflammatory gum condition that occurs when the bacteria in plaque infect the gums and ... as a scaling and root planing or SRP, and can include surgical therapies if ...
    (Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the ... studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society of ... Liegner, M.D. has compiled into a single volume a compelling argument that the disease ...
    (Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
    Breaking Medicine News(10 mins):
    (Date:2/27/2017)... , Feb. 27, 2017   Royal ... PHIA), a global leader in health technology, today ... Drug Administration (FDA) to market its ElastQ Imaging ... family of ultrasound systems. ElastQ Imaging enables simultaneous ... which is essential for the diagnosis of various ...
    (Date:2/27/2017)... PLACENTIA, Calif. , Feb. 27, 2017   ... new line of nutritional supplements using its groundbreaking new ... and 90 percent of potency through digestion per ... nutritional supplements solve the problem of nutritional waste and ... Prevent degradation during digestive processes Improve ...
    (Date:2/27/2017)... FORT WASHINGTON, Pa. , Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: ... the following upcoming investor conferences. Raymond James ... a.m. ET on March 6, 2017 in Orlando, FL. ... Care Conference at 8:00 a.m. ET on March 7, 2017 in ... at 8:30 a.m.ET on March 16, 2017 in Miami, FL. ...
    Breaking Medicine Technology: